Caution: investigational device not available for use or sale in the United States.
The MINIject first-in-human STAR-I clinical trial showed that the implantation of MINIject resulted in an average of over 40% IOP reduction to a mean of 13.8 mmHg at two years post-surgery. In addition, around half of patients were able to discontinue topical medication usage and remained medication-free at two years. There were no serious adverse events related to the device or the procedure, and no patient required additional glaucoma surgery. The STAR-II European trial showed consistent results at 6-month follow-up.